Ceria Therapeutics

📍 Tucson, United States🗓 Founded 2019👥 11 employees💰 Last funded Feb 2024
Biotechnology Research🌐 ceriatx.com
Website LinkedIn
Ceria was founded to develop products from a proprietary platform technology to treat life-threatening human diseases characterized by overactive and dysregulated immune responses. Cerias platform technology consists of a novel active pharmaceutical agent comprised of a regulatory microRNA (miR-146a) conjugated to cerium nanoparticles (CNPs). Like all nanoparticles, CNPs are actively endocytosed by all cells they contact, delivering the miR-146a payload to targeted cells. Multiple high morbidity and life-threatening conditions are characterized by dysregulated immune responses including acute respiratory distress syndrome (ARDS), diabetic foot ulcers (DFU) and ulcerative colitis (UC), representing a US market of $4B. Affected tissues in these conditions all demonstrate reduce miR-146a and are corrected by our candidate drug products. Development to date has been supported by ~$7.5m of nondilutive financing and $500k investment capital. The company is seeking up to $3m in investment capital to contribute to a first-in-man clinical study of one drug product consisting of formulated CNP-miR-146a in DFU.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Ceria Therapeutics?
Ceria Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did Ceria Therapeutics last raise funding?
The most recent investment in Ceria Therapeutics recorded on gritt.io was in February 2024.
When was Ceria Therapeutics founded?
Ceria Therapeutics was founded in 2019.
What industry is Ceria Therapeutics in?
Ceria Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Ceria Therapeutics based?
Ceria Therapeutics is headquartered in Tucson, United States.